| HOME >> MEDICINE >> TECHNOLOGY |
Patients with metastatic breast cancer live longer on average if their chemotherapy is continued after their cancer is brought under control, a new meta-analysis shows.
J. O'Shaughnessy, US
Iniparib extends overall survival in metastatic triple-negative breast cancer: final Phase-II results (embargo: 10 October, 15:30 Milan time)
Women with an aggressive subtype of metastatic breast cancer appear to live longer when treated with iniparib plus chemotherapy, compared to chemotherapy alone, the results of a randomized Phase-II trial show.
M. Pavel, DE
Phase-III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors (embargo: 11 October, 10:30 Milan time)
The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells.
B. Koczwara, AU
Fertility concerns of cancer survivors inadequately addressed, study finds (embargo: 11 October, 12:30 Milan time)
Many cancer survivors experience changes in sexual function that leave them feeling guilt and a longing for intimacy. The researchers say that these sexuality and fertility concerns are often not adequately addressed by doctors.
Y. Loriot, FR
Sexual issues a major concern for cancer patients taking new targeted drugs (embargo: 11 October, 12:30 Milan time)
New drugs that target specific molecular mechanisms of cancer have improved the treatment of cancer patients in recent years, but those benefits may come with a cost to the patient's sex life, researchers have found.
B. You, FR
Early cancer drug trials flawed by inconsistencies in prohibited drug lists, study finds (embargo: 11 October, 12:30 Milan time)
Substantial inconsistencies in a basic aspect of
'/>"/>
| SOURCE European Society for Medical Oncology (ESMO) Copyright©2010 PR Newswire. All rights reserved |